BACKGROUND: The mechanisms behind natural control of HIV replication are still unclear, and several studies pointed that elite controllers (ECs) are a heterogeneous group. METHODS: We performed analyses of virologic, genetic, and immunologic parameters of HIV-1 controllers groups: (1) ECs (viral load, <80 copies/mL); (2) ebbing elite controllers (EECs; transient viremia/blips); and viremic controllers (VCs; detectable viremia, <5000 copies/mL). Untreated noncontrollers (NCs), patients under suppressive highly active antiretroviral therapy (HAART), and HIV-1-negative individuals were analyzed as controls. RESULTS: Total and integrated HIV-1 DNA for EC were significantly lower than for NC and HAART groups. 2-LTR circles were detected in EEC (3/5) and VC (6/7) but not in EC. Although EC and EEC maintain normal T-cell counts over time, some VC displayed negative CD4 T-cell slopes. VC and EEC showed a higher percentage of activated CD8 T cells and microbial translocation than HIV-1-negative controls. EC displayed a weaker Gag/Nef IFN-γ T-cell response and a significantly lower proportion of anti-HIV IgG antibodies than EEC, VC, and NC groups. CONCLUSION: Transient/persistent low-level viremia in HIV controllers may have an impact on immunologic and virologic profiles. Classified HIV controller patients taking into account their virologic profile may decrease the heterogeneity of HIV controllers cohorts, which may help to clarify the mechanisms associated to the elite control of HIV.
BACKGROUND: The mechanisms behind natural control of HIV replication are still unclear, and several studies pointed that elite controllers (ECs) are a heterogeneous group. METHODS: We performed analyses of virologic, genetic, and immunologic parameters of HIV-1 controllers groups: (1) ECs (viral load, <80 copies/mL); (2) ebbing elite controllers (EECs; transient viremia/blips); and viremic controllers (VCs; detectable viremia, <5000 copies/mL). Untreated noncontrollers (NCs), patients under suppressive highly active antiretroviral therapy (HAART), and HIV-1-negative individuals were analyzed as controls. RESULTS: Total and integrated HIV-1 DNA for EC were significantly lower than for NC and HAART groups. 2-LTR circles were detected in EEC (3/5) and VC (6/7) but not in EC. Although EC and EEC maintain normal T-cell counts over time, some VC displayed negative CD4 T-cell slopes. VC and EEC showed a higher percentage of activated CD8 T cells and microbial translocation than HIV-1-negative controls. EC displayed a weaker Gag/Nef IFN-γ T-cell response and a significantly lower proportion of anti-HIV IgG antibodies than EEC, VC, and NC groups. CONCLUSION: Transient/persistent low-level viremia in HIV controllers may have an impact on immunologic and virologic profiles. Classified HIV controller patients taking into account their virologic profile may decrease the heterogeneity of HIV controllers cohorts, which may help to clarify the mechanisms associated to the elite control of HIV.
Authors: S L M Teixeira; N B R de Sá; D P Campos; A B Coelho; M L Guimarães; T C N F Leite; V G Veloso; M G Morgado Journal: Genes Immun Date: 2014-04-10 Impact factor: 2.676
Authors: Bharat S Parekh; M Susan Kennedy; Trudy Dobbs; Chou-Pong Pau; Robert Byers; Timothy Green; Dale J Hu; Suphak Vanichseni; Nancy L Young; Kachit Choopanya; Timothy D Mastro; J Steven McDougal Journal: AIDS Res Hum Retroviruses Date: 2002-03-01 Impact factor: 2.205
Authors: S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors Journal: Proc Natl Acad Sci U S A Date: 2000-03-14 Impact factor: 11.205
Authors: Olivier Lambotte; Guido Ferrari; Christiane Moog; Nicole L Yates; Hua-Xin Liao; Robert J Parks; Charles B Hicks; Kouros Owzar; Georgia D Tomaras; David C Montefiori; Barton F Haynes; Jean-François Delfraissy Journal: AIDS Date: 2009-05-15 Impact factor: 4.177
Authors: Carlos A Velasco-de-Castro; Beatriz Grinsztejn; Valdiléa G Veloso; Francisco I Bastos; José H Pilotto; Nilo Fernandes; Mariza G Morgado Journal: PLoS One Date: 2014-01-30 Impact factor: 3.240
Authors: Clarisa M Buckner; Lela Kardava; Xiaozhen Zhang; Kathleen Gittens; J Shawn Justement; Colin Kovacs; Adrian B McDermott; Yuxing Li; Mohammad M Sajadi; Tae-Wook Chun; Anthony S Fauci; Susan Moir Journal: J Infect Dis Date: 2016-04-27 Impact factor: 5.226
Authors: Anju Bansal; Sarah Sterrett; Nathan Erdmann; Andrew O Westfall; Jodie Dionne-Odom; Edgar T Overton; Paul A Goepfert Journal: AIDS Date: 2015-11 Impact factor: 4.177
Authors: Samara Tatielle M Gomes; Érica R Gomes; Mike B Dos Santos; Sandra S Lima; Maria Alice F Queiroz; Luiz Fernando A Machado; Izaura M V Cayres-Vallinoto; Antonio Carlos R Vallinoto; Marluísa de O Guimarães Ishak; Ricardo Ishak Journal: BMC Infect Dis Date: 2017-06-01 Impact factor: 3.090
Authors: Suwellen S D de Azevedo; Diogo Gama Caetano; Fernanda H Côrtes; Sylvia L M Teixeira; Karina Dos Santos Silva; Brenda Hoagland; Beatriz Grinsztejn; Valdilea G Veloso; Mariza G Morgado; Gonzalo Bello Journal: Retrovirology Date: 2017-05-02 Impact factor: 4.602
Authors: Trevor A Crowell; Anuradha Ganesan; Stephen A Berry; Robert G Deiss; Brian K Agan; Jason F Okulicz Journal: J Int AIDS Soc Date: 2016-03-07 Impact factor: 5.396